What LogixX Pharma does

LogixX Pharma is a specialty pharmaceutical company headquartered in Reading, United Kingdom, founded in 2010 by CEO Michael Close. The company acquires marketing and distribution rights to innovative pharmaceutical, medical device, and over-the-counter (OTC) products from partner firms that lack a UK or European presence, and commercializes those products in therapeutic areas characterized by high unmet medical need. Its portfolio spans metabolic and paediatric conditions, male and female fertility and sexual health (the company's stated primary growth segment), and includes named lines Sapropterin LogixX and LogixX Fertility, alongside a broader set of medicinal products and OTCs.

The business is asset-light and licensing-driven rather than R&D or manufacturing-driven, with revenue derived from product commercialization under licensing and royalty arrangements. Distribution is delivered through a B2B partner model across the UK and continental Europe (with partner relationships extending to Italian, German, and US-based firms) and supplemented by a direct Shopify e-commerce storefront. The company relies on a small team (1–10 employees) anchored by a CEO with prior senior roles at Merck Serono, Solvay, and Bayer, and supported since July 2020 by Chief Scientific Advisor Professor Ralf Henkel, whose academic profile includes an h-index of 41 and 167 publications.

Operationally, LogixX Pharma leverages in-house regulatory capability, including Michael Close's MHRA-approved Responsible Person designation, to handle late-phase clinical, registration, and market access activities for in-licensed products. The strategy emphasizes niche, under-served therapeutic conditions, lifecycle management, geographical expansion, and selective product transfers back to originating partners for further commercialization in adjacent areas such as oncology and rare/orphan diseases.

Name

LogixX Pharma

Legal name

LogixX Pharma Limited

Website

https://logixxpharma.co.uk

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

LogixX Pharma is a UK-based specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceuticals, medical devices, and OTCs across Europe, focusing on niche therapeutic areas with high unmet medical need such as fertility and metabolic conditions.

Ownership category

akta.pro rank

Headquarters

HQ city

Reading

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: LogixX Pharma generates revenue by acquiring rights to market and distribute innovative Pharmaceutical, Medical Device and OTC products. The company focuses on commercializing products in niche therapeutic areas with high unmet medical need.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

LogixX Pharma is a specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceutical, medical device, and OTC products across the UK and Europe. The company focuses on niche therapeutic conditions with high unmet medical need, particularly in male and female fertility, sexual health, metabolic, and paediatric markets. It provides regulatory, registration, and commercial expertise to partner companies lacking UK market presence.

Product overview

LogixX Pharma is a speciality pharmaceutical company offering a portfolio of products spanning Pharmaceuticals, Medical Devices, and OTCs. The company operates three named product lines: Sapropterin LogixX (a pharmaceutical for niche therapeutic conditions), LogixX Fertility (focused on male and female fertility and sexual health), and general Medicinal Products. The company acquires rights to market and distribute innovative products in therapeutic areas of high unmet medical need, particularly in metabolic, paediatric, and rare/orphan disease markets.

Differentiator

Problem solved

Functional benefit

Brands

• Sapropterin LogixX: Pharmaceutical product for metabolic conditions.
• LogixX Fertility

Products and services

• Sapropterin LogixX A pharmaceutical product in LogixX Pharma's portfolio targeting niche therapeutic conditions with high unmet medical need, specifically for metabolic conditions.
• LogixX Fertility A product focused on male and female fertility and sexual health, representing a significant growth area for the company and addressing conditions with high unmet medical need.
• Medicinal Products Pharmaceutical products acquired for marketing and distribution rights in Europe, focusing on metabolic and paediatric markets with emphasis on novel therapeutics commercialization in niche therapeutic areas.
• Over-the-Counter (OTC) Products Over-the-counter pharmaceutical products within the company's portfolio alongside prescription medicines and medical devices, distributed across therapeutic areas of high unmet medical need.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and minor.

• AlfasigmacoreStrategic or Co-development Partner · 1 October 2013LogixX Pharma partnered with Alfasigma in October 2013 to support the UK health science business. Michael Close led the partnership activities, providing commercial and regulatory foundation for Alfasigma's products in the UK market. This partnership represents a key strategic relationship for LogixX Pharma in establishing its commercial operations.
• Italian, German and US-based Startup CompaniesminorStrategic or Co-development PartnerLogixX Pharma has partnered with several Italian, German and US-based startup companies lacking presence in the UK market. The company provides Commercial and Regulatory foundation to support growth of these partners' products in the UK and Europe. Michael Close led these partnership activities, including supporting pharmaceutical product transfers back to originating companies for further commercialization at Group level in oncology and rare/orphan diseases.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Chiesi Farmaceutici: Chiesi is an Italian-headquartered specialty pharmaceutical group with global presence in rare diseases, respiratory, and neonatology - a profile that mirrors Alfasigma, LogixX's longstanding partner. Comparable through European specialty pharma leadership and rare/orphan disease focus.
• Consilient Health: Consilient Health is a UK-based specialty pharma company that in-licenses, markets, and distributes prescription pharmaceuticals across niche therapeutic areas. Highly comparable to LogixX in geography (UK/Ireland), business model (licensing/distribution), and therapeutic focus on underserved conditions.
• Martindale Pharma: Martindale Pharma (now part of Ethypharm) is a UK specialty pharmaceutical company focused on specialty hospital products, anaesthesia, and addiction treatments. Comparable to LogixX in UK specialty pharma distribution and concentration on niche hospital/specialist channels.
• Norgine: Norgine is a European specialty pharmaceutical company focused on gastroenterology, hepatology, and rare diseases, with a similar model of in-licensing and commercializing niche therapeutics across European markets. Comparable to LogixX in its European commercialization footprint and niche-therapeutic focus.
• Advanz Pharma: Advanz Pharma is a UK-headquartered specialty pharmaceutical company focused on niche/rare disease medicines in Europe. Directly comparable to LogixX in geography (UK base), business model (specialty pharma licensing and commercialization), and therapeutic emphasis on underserved conditions.
• Swedish Orphan Biovitrum (SOBI): SOBI is a European specialty biopharmaceutical company focused on rare diseases. Comparable to LogixX in the rare/orphan disease commercialization focus and European market footprint, though at substantially greater scale.
• Recordati: Recordati is an Italian specialty pharmaceutical group with a European presence in rare diseases, cardiovascular, and urology products. Comparable to LogixX through its Italian heritage (similar to Alfasigma partner profile), niche-therapeutic emphasis, and in-licensing/commercialization approach in Europe.

Broad incumbents

• Almirall: Almirall is a European specialty pharmaceutical company with broad dermatology and specialty therapeutic franchises across Europe. Comparable to LogixX in European specialty pharma footprint and in-licensing heritage, though at significantly larger scale and broader portfolio scope.

Emerging players

• Alfasigma: Alfasigma is an Italian specialty pharmaceutical company and LogixX's longest-standing partner (since October 2013). Relevant as both a peer in Italian-headquartered specialty pharma and as the upstream licensor supplying products to LogixX for UK commercialization.

Others

• Shard Speciality Pharma: Shard Speciality Pharma is a UK specialty pharmaceutical company where LogixX CEO Michael Close serves as a board member. Relevant as an adjacent UK specialty pharma player with shared leadership overlap, providing insight into the broader UK specialty distribution landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/logixxpharmaUK
• Facebookfacebook.com/logixxpharma
• LinkedInlinkedin.com/company/logixx-pharma-solutions-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LogixX Pharma